Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study
Active, not recruiting · NCT04392505 · Registry updated 2024-02-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, cancer, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2024-02-29 | NCT04392505 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Oslo University Hospital | 327 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Haukeland Universitetssykehus | Bergen | Norway | 7 |
| National Cancer Institute | Vilnius | Lithuania | 6 |
| North Estonia Medical Centre | Tallinn | Estonia | 4 |
| Oslo University Hospital | Oslo | Norway | 111 |
| Oulu University Hospital | Oulu | Finland | 44 |
| St. Olavs hospital | Trondheim | Norway | 17 |
| Stavanger University Hospital | Stavanger | Norway | 36 |
| Tampere University Hospital | Tampere | Finland | 29 |
| Turku University Hospital | Turku | Finland | 61 |
| Universitetssykehuset i Nord-Norge | Tromsø | Norway | 3 |